These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33125391)

  • 21. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
    Garcês S; Demengeot J; Benito-Garcia E
    Ann Rheum Dis; 2013 Dec; 72(12):1947-55. PubMed ID: 23223420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases.
    Witoelar A; Jansen IE; Wang Y; Desikan RS; Gibbs JR; Blauwendraat C; Thompson WK; Hernandez DG; Djurovic S; Schork AJ; Bettella F; Ellinghaus D; Franke A; Lie BA; McEvoy LK; Karlsen TH; Lesage S; Morris HR; Brice A; Wood NW; Heutink P; Hardy J; Singleton AB; Dale AM; Gasser T; Andreassen OA; Sharma M;
    JAMA Neurol; 2017 Jul; 74(7):780-792. PubMed ID: 28586827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
    Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
    Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Kurnool S; Nguyen NH; Proudfoot J; Dulai PS; Boland BS; Vande Casteele N; Evans E; Grunvald EL; Zarrinpar A; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1472-1479. PubMed ID: 29665045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of HLA-DQA1*05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice.
    Pérez Pérez J; Escobar Ortiz J; Franco Moreno AI; Plaza Santos MDR; Castillo Pradillo M; Ponferrada Díaz Á
    Gastroenterol Hepatol; 2024 Oct; 47(8):869-871. PubMed ID: 38266819
    [No Abstract]   [Full Text] [Related]  

  • 31. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X; Gottenberg JE; Ravaud P; Combe B
    Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
    Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
    Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis.
    Bellur S; McHarg M; Kongwattananon W; Vitale S; Sen HN; Kodati S
    JAMA Ophthalmol; 2023 Feb; 141(2):150-156. PubMed ID: 36547953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
    Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
    Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
    Bachelet D; Hässler S; Mbogning C; Link J; Ryner M; Ramanujam R; Auer M; Hyldgaard Jensen PE; Koch-Henriksen N; Warnke C; Ingenhoven K; Buck D; Grummel V; Lawton A; Donnellan N; Hincelin-Mery A; Sikkema D; Pallardy M; Kieseier B; Hemmer B; Hartung HP; Soelberg Sorensen P; Deisenhammer F; Dönnes P; Davidson J; Fogdell-Hahn A; Broët P;
    PLoS One; 2016; 11(11):e0162752. PubMed ID: 27806057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases.
    Li CY; Yang TM; Ou RW; Wei QQ; Shang HF
    BMC Med; 2021 Feb; 19(1):27. PubMed ID: 33541344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
    Jung YS; Han M; Park S; Cheon JH
    Gut Liver; 2021 Jan; 15(1):92-99. PubMed ID: 32839359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
    Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
    J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.